Clinical Trials Logo

Filter by:
NCT ID: NCT03510676 Completed - Clinical trials for Peripheral Arterial Disease

The ILLUMINA Study. (ILLUMINA)

ILLUMINA
Start date: January 26, 2016
Phase: N/A
Study type: Interventional

The aim of the prospective, multicentre, single-arm study is to assess safety and efficacy of a drug eluting stent in Nitinol alloy (NiTiDES) in term of vessel patency and composite event-free survival rate up to two years follow-up in focal/medium length lesions in patients with ischemic obstruction of superficial femoral arteries or/and proximal popliteal arteries.

NCT ID: NCT03510403 Completed - Clinical trials for Obstructive Sleep Apnea

Efficacy, Safety and Acceptability of Nastentâ„¢ in Snoring and Obstructive Sleep Apnea

Start date: April 12, 2018
Phase: N/A
Study type: Interventional

This study evaluates the efficacy, the tolerance and the acceptability/compliance of the nasal airway stent, Nastent, for the treatment of mild to moderate OSA and snoring in European adult patients without cardiovascular and/or respiratory comorbidities/disorders.

NCT ID: NCT03510039 Completed - Anxiety Clinical Trials

Early Intervention AND NURSING Support for an " Involuntary Commitment Procedure " for a Close Relative

Vécu/Tiers/Psy
Start date: March 15, 2018
Phase: N/A
Study type: Interventional

In a context of first hospitalization under the constraint of a relative in psychiatric emergencies: - effect of an early intervention and a 6-month nursing follow-up on the anxious experience of third party persons - effect of nursing support on family dynamics, on the durability of outpatient care and adherence

NCT ID: NCT03509805 Completed - Obesity Clinical Trials

Sleep Apnea Syndrome in Obese Women During Pregnancy

Start date: September 1, 2010
Phase: N/A
Study type: Interventional

Excess weight or obesity is associated with an increased risk of health disorders: high blood pressure, diabetes, cardiovascular risks, dyslipidemia and sleep apneas. During pregnancy in obese women, the risk of preeclampsia increases by three and the risk of fetal death in utero by five. Snoring and Obstructive sleep apnea (OSA) may be associated with increased risk of adverse pregnancy outcomes, including maternal cardio pulmonary status, fetal heart rate and fetal acidosis-basis status by recurrent upper-airway obstruction, hypoventilation, and intermittent nocturnal hypoxia. Reports in pregnancy have identified in association with OSA and preeclampsia, intrauterine growth restriction and stillbirth. The prevalence of OSA among women is estimated to be 2-5%, but it remains underdiagnosed during pregnancy. In sleep apnea syndrome, a few data have shown better pregnancy and fetal outcome with the use continuous positive airway pressure (CPAP) therapy. the hypothesis is in obese pregnant women that there could be a significant association between sleep apnea syndrome and hypertensive disorders, preeclampsia and adverse fetal outcomes This is a prospective study of Women with a body mass index of 35 kg.m2 or greater. The aim of this study is to determinate the prevalence of sleep apnea syndrome in obese pregnant women and the benefit of CPAP on the maternal and fetal outcome.

NCT ID: NCT03509051 Completed - Clinical trials for Hematopoietic Stem Cell Transplant

Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation

MENINGREF
Start date: June 1, 2019
Phase: N/A
Study type: Interventional

Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at risk of various bacterial infections, especially due to a progressive decrease of specific antibodies. Around 90% of HSCT recipients have unprotective titers of specific antibodies to serogroups A and C meningogocci (Parkkali 2001; Mahler 2012). Some small studies suggest that the response to meningococcal A and C vaccines is close to 100% after 3 doses given 18 months after transplant. Although the response to 2 doses of 4CMenB is over 75% in other immunocompromised patients (Feavers, 2017), studies with 4CMenB are lacking after HSCT. Nevertheless, as serogroup B caused 74% of IMD in Europe between 2004-2014 (Whittaker, 2017), the meningococcal B vaccination is recommended by the more recent guidelines from 6 months after transplant. There are, however, no data on the safety and efficacy of this vaccine after hematopoietic stem cell allograft (HSCT). The objective of this study is to assess the response to 2 doses of a multicomponent meningococcal B vaccine (4CMenB) given at 2 months interval in adult allogeneic HSCT recipients transplanted at least 6 months ago. The response will be assessed 1 month and 10 months after the second dose of vaccine by measuring bactericidal antibodies against NadA, fHbp, NHBA and PorAP1 vaccinal antigens according to methods previously reported (Caron Lancet Infect Dis 2011). The response rate will be correlated to pre- and post-transplant factors. The hypothesis of this study is that 80% of the patients should have protective titers one month after the 2nd dose.

NCT ID: NCT03508947 Completed - Clinical trials for Duchenne Muscular Dystrophy

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

Start date: January 24, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, double-blind, placebo-controlled, single ascending dose cohort study to evaluate the safety, tolerability, and plasma concentrations of WVE-210201 in ambulatory and non-ambulatory male pediatric patients with DMD amenable to exon 51 skipping intervention.

NCT ID: NCT03508206 Completed - Healthy Clinical Trials

Acute Effect of a Standardized Botanical Blend Rich in Polyphenols on Cognitive Functions in Healthy Students

Start date: November 13, 2017
Phase: N/A
Study type: Interventional

Available literature suggests that flavanols-rich foods, and more especially monomeric flavanols-rich foods such as grape, can have an acute effect on cognitive functions via different mechanisms such as cerebral blood flow improvement. The objective of this study is to investigate the effect of a Standardized botanical blend rich in polyphenols (SBRP), on cognitive functions, together with endothelial function in healthy students. Moreover, in order to provide supportive evidence on the mechanisms and biological plausibility to the clinical effects of the product, appropriate biological parameters and circulating metabolites will be assayed. The study design will be a double-blind, randomised, placebo controlled, crossover study. A total of 30 healthy volunteers will be included. Each participant will receive a single dose of SBRP and placebo capsules, during 2 separate experimental visits and in a counterbalanced order. There will be a 1 week washout period between the 2 experimental visits. During each experimental visit, after a training battery volunteers will be administered a cognitive test battery (COMPASS) before product intake and 6 times after product intake (B1 to B6, from 90 min post-dose to 160 min post-dose).

NCT ID: NCT03508180 Completed - Clinical trials for Lung Cancer and Cancer of Digestive System

Benefit Evaluation of Foot Reflexology in Oncology

REFYO-R
Start date: June 14, 2018
Phase: N/A
Study type: Interventional

Chemotherapy with platinum salts is very emetic. The aim of this study is to evaluate the benefits of foot reflexology in nausea and vomiting induced by platinum salts-based chemotherapy in patients with thoracic or digestive tumors.

NCT ID: NCT03508024 Completed - Lewy Body Disease Clinical Trials

Patients With Alzheimer's Disease or Related Youth Disease

PARMAAJJ
Start date: January 5, 2018
Phase:
Study type: Observational

This study aims to determine factors related to diagnosis delay for patients with young onset dementia (first symptoms before 60 years old) who live in North of France.

NCT ID: NCT03507777 Completed - Clinical trials for Coronary Artery Disease

ILUMIEN IV: OPTIMAL PCI

Start date: May 17, 2018
Phase: N/A
Study type: Interventional

The objective of this prospective, single-blind clinical investigation is to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent implantation strategy in achieving larger post-PCI lumen dimensions and improving clinical cardiovascular outcomes in patients with high-risk clinical characteristics and/or with high-risk angiographic lesions.